VGLS Stock Overview
VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
VG Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 9,900.00% |
| 3 Month Change | 0% |
| 1 Year Change | 100.00% |
| 3 Year Change | -98.59% |
| 5 Year Change | -98.32% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| VGLS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -3.7% |
| 1Y | 100.0% | -2.0% | 20.5% |
Return vs Industry: VGLS exceeded the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: VGLS exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| VGLS volatility | |
|---|---|
| VGLS Average Weekly Movement | 7,280.7% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VGLS's share price has been volatile over the past 3 months.
Volatility Over Time: VGLS's weekly volatility has increased from 6493% to 7281% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | Haig Keledjian | www.vglifesciences.com |
VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers.
VG Life Sciences Inc. Fundamentals Summary
| VGLS fundamental statistics | |
|---|---|
| Market cap | US$2.11m |
| Earnings (TTM) | -US$4.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs VGLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VGLS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.30m |
| Earnings | -US$4.30m |
Last Reported Earnings
Sep 30, 2015
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did VGLS perform over the long term?
See historical performance and comparison